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Abstract
Objectives. Indirect comparisons via a common comparator (anchored comparisons) are
commonly used in health technology assessment. However, common comparators may not
be available, or the comparison may be biased due to differences in effect modifiers between
the included studies. Recently proposed population adjustment methods aim to adjust for dif-
ferences between study populations in the situation where individual patient data are available
from at least one study, but not all studies. They can also be used when there is no common
comparator or for single-arm studies (unanchored comparisons). We aim to characterise the
use of population adjustment methods in technology appraisals (TAs) submitted to the United
Kingdom National Institute for Health and Care Excellence (NICE).
Methods. We reviewed NICE TAs published between 01/01/2010 and 20/04/2018.
Results. Population adjustment methods were used in 7 percent (18/268) of TAs. Most appli-
cations used unanchored comparisons (89 percent, 16/18), and were in oncology (83 percent,
15/18). Methods used included matching-adjusted indirect comparisons (89 percent, 16/18)
and simulated treatment comparisons (17 percent, 3/18). Covariates were included based
on: availability, expert opinion, effective sample size, statistical significance, or cross-valida-
tion. Larger treatment networks were commonplace (56 percent, 10/18), but current methods
cannot account for this. Appraisal committees received results of population-adjusted analyses
with caution and typically looked for greater cost effectiveness to minimise decision risk.
Conclusions. Population adjustment methods are becoming increasingly common in NICE
TAs, although their impact on decisions has been limited to date. Further research is needed
to improve upon current methods, and to investigate their properties in simulation studies.
Health technology assessments and appraisals require reliable estimates of relative treatment
effects to inform reimbursement decisions. When head-to-head evidence is not available
but the two treatments of interest have each been studied against a common comparator
(e.g., placebo or standard care), a standard indirect comparison may be performed using pub-
lished aggregate data from each study (1). With larger numbers of treatments and studies a
network meta-analysis is the standard approach, of which indirect comparison is a simple spe-
cial case (2;3). Standard indirect comparisons and network meta-analyses assume that the dis-
tributions of any effect modifying variables are similar in each study population and the
decision target population, so that relative effects are constant across populations (the con-
stancy of relative effects assumption).
These methods are widely used in health technology appraisals, such as those undertaken
by the National Institute for Health and Care Excellence (NICE) in the United Kingdom. As
part of the NICE technology appraisal process, a company submits evidence on the clinical
effectiveness of their treatment compared with other relevant treatments, frequently informed
by indirect comparisons or network meta-analysis. The submitting company will have individ-
ual patient data (IPD) available from their own trial or trials, but very often only published
aggregate data (AgD) from those of their competitors. More recently, methods have been pro-
posed which use the available IPD to adjust for differences between IPD and AgD study pop-
ulations. These include matching-adjusted indirect comparison (MAIC) (4) and simulated
treatment comparison (STC) (5), both first introduced in 2010, which use re-weighting or
regression, respectively, to adjust the IPD estimates to the AgD study population.
MAIC is a re-weighting method, where weights are derived for the individuals in the IPD
study such that the moments of the weighted covariate distribution match the covariate sum-
maries reported in the AgD study (typically using mean and variance for continuous
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covariates, and proportions for categorical covariates). The
weights are then used to obtain predicted outcomes in the AgD
study population, for example by taking weighted mean outcomes
on each treatment. STC is a regression adjustment method, where
a regression model is fitted in the IPD study. This model is then
used to predict average outcomes in the AgD study population.
Whichever method is used, once the predicted outcomes are
obtained for the AgD study population these are compared with
the outcomes reported by the AgD study. The development and
use of these methods is motivated by one of two reasons: either
(i) there is evidence for effect modification, and these variables
are distributed differently in each study population; or (ii) there
is no common comparator or the relevant studies are single
arm, and so adjustment is required for all prognostic and effect
modifying variables.
Phillippo et al. (6;7) reviewed the properties and assumptions
of population adjustment methods and provided recommenda-
tions for their use in submissions to NICE. As summarised in
Table 1, population adjustment in anchored scenarios (where a
common comparator is available) relaxes the constancy of relative
effects assumption (to conditional constancy of relative effects) by
adjusting for effect modifiers. In unanchored scenarios, a much
stronger assumption is required (conditional constancy of abso-
lute effects), because it is necessary to reliably predict absolute
outcomes. This requires all effect modifiers and prognostic vari-
ables to be adjusted for, and is very difficult to achieve or justify,
either empirically or otherwise. As such, unanchored comparisons
are subject to unknown amounts of residual bias due to unob-
served prognostic variables and effect modifiers (6;7).
Although statistical theory is clear on which variables must be
adjusted for to obtain an unbiased indirect comparison, in prac-
tice variable selection requires judgement and justification (6).
For anchored comparisons, evidence of effect modifier status on
the chosen scale should be provided before analysis.
Unanchored comparisons are very difficult to justify, but a prin-
cipled approach to selecting variables before analysis should be
taken to avoid “gaming.”
The level of overlap in the covariate distributions between the
IPD and AgD study populations is another key property of pop-
ulation adjusted indirect comparisons. For regression-based
methods such as STC, the lesser the overlap the greater the
amount of extrapolation required, which requires additional
assumptions to be valid. For re-weighting methods such as
MAIC, extrapolation is simply not possible; sufficient overlap is,
therefore, crucial for re-weighting methods. As well as checking
the distributions of the covariates in each study, a simple indicator
of the amount of overlap is the effective sample size (ESS), which
may be calculated from the weights (6). Large reductions in ESS
may indicate poor overlap between the IPD and AgD studies;
small absolute ESS shows that the comparison is dependent on
a small number of individuals in the IPD study and may be
unstable.
MAIC and STC were both designed with simple indirect com-
parisons in mind and do not generalize naturally to larger net-
works of studies or treatments, where there may be multiple
comparators of interest and/or multiple aggregate study popula-
tions. We are, therefore, interested in the prevalence of such sce-
narios in NICE TAs, to determine how larger network structures
have been handled using current methods and to motivate the
development of more appropriate methods. In this study, we
undertake a comprehensive review of technology appraisals
(TAs) published by NICE (8), aiming to characterize the use of
population adjustment methods. As well as investigating the
uptake of population adjustment in different clinical areas, we
are interested in the ways in which these methods are used and
whether the key assumptions are likely to hold, to assess the ade-
quacy of current practice for decision making. We discuss how
these methods have been received by appraisal committees and
how they have impacted decision making. We conclude with a
discussion, and suggest several key improvements to current prac-
tice, toward providing better evidence for decision makers and
greater impact for submitting companies.
Methods
We reviewed all NICE TAs published between January 1, 2010,
and April 20, 2018, for the use of population adjustment methods.
We excluded appraisals that had access to IPD from all included
studies, and focussed on those with only partial availability of
IPD. From those appraisals using one or more forms of popula-
tion adjustment, we extracted the following information from
company submissions: Population adjustment method used;
Whether the comparison was anchored or unanchored;
Outcome type; Clinical area; Number of covariates adjusted for;
How the covariates were chosen; For appraisals using MAIC,
effective sample sizes after weighting; Whether a larger network
structure was present (e.g., multiple comparators and/or aggregate
studies), and how this was dealt with.
Screening and data extraction were carried out by a single pri-
mary reviewer (D.M.P.).
Results
A total of 268 technology appraisals have been published by NICE
since 2010, when MAIC and STC were first suggested in the lit-
erature (4;5), up until April 20, 2018. Of these, twenty-one
appraisals used a form of population adjustment; three of these
had IPD available from all included studies, so we focus on the
remaining eighteen appraisals with only partial IPD. Figure 1
shows the selection process. The included appraisals are tabulated
in Supplementary Table 1.
The first use of population adjustment in a TA was TA311 in
2014. Since then, the use of population adjustment in TAs has
increased rapidly, in terms of both the absolute number and the
relative proportion of appraisals using population adjustment
methods (Figure 2). In 2017, a total of nine appraisals used pop-
ulation adjustment, accounting for 14.5 percent of all appraisals
that year.
Usage by Clinical Area
Since 2010, almost half of all published TAs have been in oncol-
ogy (127 of 268; 47.4 percent). Of these, fifteen (11.8 percent)
used population adjustment, accounting for over 80 percent of
all applications of population adjustment in appraisals to date.
Only two other clinical areas saw any applications of population
adjustment: two out of twelve (16.7 percent) appraisals in hepatol-
ogy (both for hepatitis C), and one out of 28 (3.6 percent)
appraisals in rheumatology. The usage of population adjustment
methods in oncology TAs has increased since 2010, both in
terms of the number and proportion of TAs using these methods.
In 2017, a total of nine appraisals in oncology (25.7 percent) used
population adjustment methods, up from one appraisal (9.1 per-
cent) in 2014 (Figure 3). The increasing use of population
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adjustment in oncology appraisals, which themselves make up the
largest proportion of all appraisals, is the main driver behind the
overall results in Figure 2.
Outcome Types
Unsurprisingly, due to the majority of applications of population
adjustment being in oncology appraisals, survival outcomes (e.g.,
progression-free survival, overall survival) were the most common
outcome type used in population-adjusted analyses, thirteen of
eighteen appraisals (72.2 percent) included a population-adjusted
survival outcome. Rate outcomes such as response rates were
used in five appraisals, and duration and change from baseline out-
comes in one appraisal each. Two appraisals (TA462, TA451) used
population adjustment for more than one type of outcome (survival
and response rate, and response rate and duration, respectively).
Population Adjustment Method
The large majority of appraisals using some form of population
adjustment used MAIC (16 of 18; 88.9 percent). STC was less
popular, used in only three appraisals (16.7 percent). Two
appraisals used both MAIC and STC and compared the results,
which were reported to be similar in each case (TA383, TA492).
One appraisal (TA410) used neither MAIC nor STC. In this
appraisal, a published prediction model (developed for a previous
appraisal) (9) was used to adjust the survival curves from the AgD
trials to the population of the IPD trial.
Of the sixteen appraisals performing MAIC, only nine (56.3
percent) reported an effective sample size. Of these, the median
effective sample size was 80.0 (range: 4.0 to 335.5, interquartile
range [IQR]: 15.4 to 52.0), with a median reduction in effective
sample size from the original sample size of 74.2 percent
(range: 7.9 percent to 94.1 percent, IQR: 48.0 percent to 84.6 per-
cent). Such large reductions in ESS indicate that in many cases
there may be poor overlap between the IPD and AgD studies. A
substantial proportion of TAs reported small absolute ESS, and
the resulting comparisons are, therefore, dependent on a small
number of individuals in the IPD study and may be unstable.
Anchored and Unanchored Comparisons
Only two of eighteen appraisals (11.1 percent) formed anchored
comparisons (TA383, TA449). The remaining sixteen appraisals
(88.9 percent) instead formed unanchored comparisons without
a common comparator, relying on strong assumptions that are
very difficult to justify and are thus subject to unknown amounts
of residual bias. No appraisals attempted to quantify residual bias,
although this is challenging to achieve (6). Appraisal committees
and review groups treated estimates from unanchored compari-
sons with strong caution.
Covariates Adjusted for
For appraisals reporting unanchored comparisons, the median
number of covariates adjusted for was six, and ranged from one
to thirteen covariates. Only one of the two appraisals reporting
anchored comparisons presented any information on the choice
of covariates; in this appraisal (TA383) ten covariates were
adjusted for.
Common covariates adjusted for in oncology appraisals were
age, Eastern Cooperative Oncology Group (ECOG) performance
status, gender, and the number and/or type of previous therapies.
Many appraisals also adjusted for other clinical factors such as
biomarker levels or disease subtypes.
Both hepatitis C appraisals (TA364, TA331) adjusted for age,
body mass index, gender, fibrosis staging, and viral load. One
appraisal (TA364) further adjusted for race, genotype, and several
biomarker levels in two MAIC analyses for different genotypes
and comparator treatments, but in a third MAIC analysis only
had sufficient sample size to adjust for viral load.
The single rheumatology appraisal (TA383) adjusted for ten
covariates including age, gender, race, concomitant treatments,
two biomarkers, and three functional/activity scores.
The most common justification for covariate selection amongst
appraisals reporting unanchored comparisons was simply to
adjust for all baseline characteristics reported in both studies.
This was also true for appraisal TA383 which used an anchored
comparison, despite the fact that adjustment is only required
for covariates which were effect modifiers in anchored compari-
sons. (The other appraisal with an anchored comparison,
TA449, did not report any information on variable selection.)
Unnecessary adjustment will not introduce bias but may increase
uncertainty, particularly with MAIC (6) (although we note that
TA383 took place before the advice in Phillippo et al. (6) was pub-
lished). Two appraisals (TA429, TA457) justified the selection of
covariates using expert clinical opinion. One appraisal using
MAIC (TA510) asked experts to rank covariates by importance,
then added covariates into the model one-by-one in decreasing
Table 1. All indirect comparisons and meta-analyses require some form of constancy assumption.
Anchored comparisons Unanchored comparisons
Method
Standard indirect comparison or
meta-analysis
Anchored population-adjusted
indirect comparison
Unanchored population-adjusted indirect
comparison
Constancy
assumption
Constancy of relative effects Conditional constancy of relative
effects
Conditional constancy of absolute effects
⇒ Relative effects are the same
across populations
⇒ Reliable predictions of relative
effects
⇒ Reliable predictions of absolute effects
Valid only if No effect modifiers in imbalance All effect modifiers known and
adjusted for
All effect modifiers and prognostic variables
known and adjusted for
Data
requirements
Aggregate data IPD on at least one trial IPD on at least one trial
Note. Unanchored comparisons require a much stronger assumption, which is widely considered impossible to meet.
IPD, individual patient data.
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order of importance; the final model choice was determined by
consideration of effective sample size.
Unanchored MAICs in particular have to make trade-offs
between effective sample size and the number of adjustment var-
iables, because the number of potential prognostic factors is likely
to be large. However, unless all prognostic factors and effect mod-
ifiers are included in the adjustment, the estimates will remain
biased (6). Moreover, the covariates for which the effective sample
size reduction is greatest are those which are most imbalanced
between populations, and are, therefore, more important to adjust
for amongst the covariates with similar prognostic or effect mod-
ifying strength. Two appraisals using STC used statistical tech-
niques to choose covariates. One (TA333) selected covariates
that were “significant” in the regression model, which is again
likely to incur residual bias, particularly in small samples (10).
Another (TA492) selected covariates to maximise cross-validated
predictive performance, which is more appropriate given that STC
relies on accurate predictions into the aggregate population, but is
still subject to the limitations of in-sample validation (6).
Larger Networks
As originally proposed, MAIC and STC cannot be extended to
larger network structures with multiple comparators of interest
and/or multiple aggregate studies. However, these scenarios fre-
quently arise in practice: a total of ten of eighteen TAs (55.6 per-
cent) involved larger networks of treatments and studies.
In five of these (71.4 percent; TA331, TA383, TA429, TA500,
TA510), multiple population adjusted indirect comparisons were
performed and then simply left as stand-alone estimates. Each
of these estimates will be valid for different target populations,
and so cannot be interpreted together coherently unless addi-
tional assumptions are met, namely that all the target populations
are in fact identical (in terms of effect modifiers for anchored
comparisons, and also in terms of prognostic variables for unan-
chored comparisons).
One appraisal (TA492) used STC (and MAIC as a sensitivity
analysis) to predict active treatment arms for each single-arm
study in an unconnected network, and then analysed this newly
connected network using network meta-analysis (NMA). This
results in a coherent set of relative effect estimates (11).
However, aside from the very strong assumptions required for
the unanchored comparisons, this analysis must also assume
that there are no imbalances in effect modifiers between the
single-arm studies included in the NMA. Another serious con-
cern is the repeated use of the predicted active treatment arms,
which are all based on the same data set and so are not
independent.
Two appraisals (TA311, TA380) had wider networks of treat-
ments and studies including the two treatments of primary inter-
est, but that were not fully connected. These networks were
analysed using NMA (without any population adjustment)
using an equivalency assumption for two treatments (TA311)
and a matched pairs analysis (TA380) to connect the networks.
Separate unanchored MAICs were then used to create
population-adjusted comparisons as sensitivity analyses.
One appraisal (TA427) had additional single-arm IPD sources
which were used to provide additional stand-alone comparisons
(in this case using Cox regression for survival outcomes).
Lastly, the method of analysis was unclear for one appraisal
(TA364) which had multiple comparators of interest, some with
several aggregate studies available. However, given that unan-
chored MAIC was used, this analysis is susceptible to the same
sets of pitfalls described above depending on whether the esti-
mates were left as stand-alone estimates or synthesised as a
network.
Discussion
In this review, we have focussed on the use of population adjust-
ment methods in NICE Technology Appraisals. Different prac-
tices may be found in submissions to other reimbursement
agencies, who may also receive and interpret such analyses differ-
ently, and outside of the technology appraisal context. A general
review of applications in the literature has previously been pub-
lished by Phillippo et al. (6) and found similar issues to those
Fig. 1. Flow chart showing the process of selecting technol-
ogy appraisals, and the numbers excluded and remaining at
each stage. IPD, individual patient data; NICE, United
Kingdom National Institute for Health and Care Excellence;
TA, technology appraisal.
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discussed here, although with even greater variation in analysis
practices. This review of TAs also spans a limited time period
(8 years) since these methods were first published. Practice is
likely to continue to evolve, for example as methodological guid-
ance is published (6). A further limitation of this review is that the
data extraction was carried out by a single reviewer only.
Population adjustment methods (and in particular unanchored
MAIC) have been used in NICE TAs either as the main source of
comparative clinical effectiveness, or as supportive evidence
alongside the company’s base-case analysis. Although these meth-
ods may account for some differences between study populations
that conventional indirect comparison methods cannot, appraisal
committees were often concerned by the quality of the estimates
they produced. This was not necessarily due to inherent method-
ological limitations; rather, the methods were used in situations
where the data underpinning the analyses were often weak (for
example, immature follow-up data or small single arm studies).
Furthermore, population-adjusted comparisons were often
associated with uncertainty regarding the covariates that were
adjusted for, specifically, which ones were selected for adjustment,
how they were selected, and whether and to what extent any
unobserved characteristics biased the analysis. A key challenge
to appraisal committees, especially with unanchored compari-
sons, was where to draw the line between the number of variables
to adjust for and the precision of the resulting estimates. This was
particularly apparent for MAIC, where the effective sample size
decreases with each additional covariate adjusted for.
In NICE TAs, decisions are not based solely on clinical effec-
tiveness; cost considerations are also taken into account in a
cost-effectiveness analysis, summarised by an incremental cost-
effectiveness ratio (ICER). The impact of evidence from
population-adjusted indirect comparisons is, therefore, under-
stood within this context. In some instances, appraisal committees
could not make a positive recommendation for the technology
because the uncertainty in the population-adjusted estimates
were not offset by a sufficiently low ICER to manage the decision
risk. Where the appraisal committee made a positive recommen-
dation, the committee typically compared the most plausible
ICER against the lower end of the acceptable range (requiring
the technology to be more cost effective) to minimise the risks
associated with uncertainty. Where appraisal committees judged
a technology to have plausible potential to be cost-effective,
they often recommended the use of the technology with interim
funding as part of a data collection arrangement.
In general, appraisal committees tended to use population
adjustment methods for decision-making when they were pre-
sented alongside an alternative, confirmatory analysis, and when
the uncertainty in the method was acknowledged, described,
and explored as far as possible (for example using sensitivity anal-
yses). Appraisal committees have previously suggested that com-
panies should also consider validating the results of their
analyses (e.g., TA510), for example by estimating the effect of
the technology using population adjustment methods in an exter-
nal cohort (such as registry data) and comparing that estimate
with the observed effect of the technology in that cohort.
Population adjustment methods are becoming ever more prev-
alent in NICE TAs. The majority were unanchored with no com-
mon comparator, and hence rely on very strong assumptions as
outlined in Table 1. The proliferation of unanchored analyses is
likely to escalate, in large part due to the rise of single-arm studies
for accelerated or conditional approval with regulators such as the
US Food and Drug Administration or the European Medicines
Agency (12). However, the evidential requirements for demon-
strating clinical efficacy (to obtain licensing) can be less stringent
than those for demonstrating cost effectiveness (to obtain reim-
bursement). NICE appraisal committees and evidence review
groups have been justifiably wary of the use of unanchored pop-
ulation adjustment methods to bridge this evidence gap, with
Fig. 2. The number and percentage of NICE technology
appraisals using population adjustment methodology has
increased greatly since the introduction of these methods
in the literature in 2010. *Two TAs used population adjust-
ment out of twenty-five up to April 20, 2018. NICE, United
Kingdom National Institute for Health and Care Excellence;
TA, technology appraisal.
International Journal of Technology Assessment in Health Care 5
KWWSVGRLRUJ6
'RZQORDGHGIURPKWWSVZZZFDPEULGJHRUJFRUH8QLYHUVLW\RI<RUNRQ-XQDWVXEMHFWWRWKH&DPEULGJH&RUHWHUPVRIXVHDYDLODEOHDWKWWSVZZZFDPEULGJHRUJFRUHWHUPV
many commenting that the results should be interpreted with
caution and may contain an unknown amount of bias. As such,
committees typically looked for greater cost effectiveness (lower
ICER) to minimise the decision risk resulting from clinical effec-
tiveness evidence perceived to be uncertain and poor quality.
Increased dialogue between regulators and reimbursement agen-
cies may help bridge this gap in evidence requirements.
All current population adjustment methods assume that there
are no unmeasured effect modifiers when making anchored com-
parisons. For unanchored comparisons, it is further assumed that
there are no unmeasured prognostic factors. This latter assump-
tion is particularly strong and difficult to justify. Some suggestions
for quantifying residual bias due to unmeasured confounding are
made by Phillippo et al. (6), and this is an area for further work.
Several technology appraisals had multiple comparators and/or
AgD study populations for which comparisons were required.
Current MAIC and STC methodology cannot handle larger net-
work structures: multiple analyses were performed in each case,
and then either left as stand-alone comparisons or themselves
synthesised using network meta-analysis, requiring further
assumptions in the process. Furthermore, current MAIC and
STC methods produce estimates which are valid only for the
aggregate study population (typically that of a competitor) with-
out additional assumptions, which may not match the target pop-
ulation for the decision (6). This fact has been largely overlooked
in appraisals to date, although one appraisal (TA451) did note
that the MAIC analysis that was performed took the results of
an IPD trial deemed to be relevant to the decision population
and adjusted them into a nonrepresentative aggregate trial
population.
Clearly, if effect modification is present then it is not enough
to simply produce “unbiased” estimates: the estimates produced
must be specific to the decision population, otherwise they are
of little use to decision-makers. This motivates the need to
develop new methods which can extend naturally to larger net-
works of treatments, and can produce estimates for a given target
decision population. Furthermore, if all trials are a subset of the
decision target population with respect to one or more effect
modifiers, then any adjustment must rely on extrapolation; if
these effect modifiers are discrete, adjustment may be impossible.
The large majority of technology appraisals used MAIC to
obtain population-adjusted indirect comparisons. Effective sam-
ple sizes were typically small and often substantially reduced com-
pared with the original sample sizes, indicating potential lack of
overlap between the IPD and AgD populations. Lack of overlap
is of particular concern with re-weighting methods such as
MAIC, because they cannot extrapolate to account for covariate
values beyond those observed in the IPD and, thus, may produce
estimates that remain biased even when all necessary covariates
are included in the model (6). This motivates the need for simu-
lation studies to explore the robustness of MAIC (and other pop-
ulation adjustment methods) in scenarios where there is a lack of
overlap between populations.
Three appraisals were excluded from our review, as IPD were
available from all included studies (13–15). These appraisals
were all unanchored comparisons of survival outcomes in oncol-
ogy, and used a selection of propensity score, covariate matching,
and regression methods. Having IPD available from all studies is
the gold-standard and is preferable if at all possible. This is
because IPD allows for analyses that have more statistical power
and may rely on less stringent assumptions, and allows assump-
tions to be tested. Separate methodological guidance is available
for analyses with full IPD (16).
For population-adjusted analyses to have the desired impact on
decision making in technology appraisals, several key improve-
ments are needed to current practice in line with recent guidance
(6). First, a target population relevant to decision makers should
be defined, and estimates must be produced for this population to
Fig. 3. For technology appraisals in oncology, the number
and percentage using population adjustment methodology
has increased greatly since the introduction of these meth-
ods in the literature in 2010. *Two TAs used population
adjustment out of twelve up to April 20, 2018. TA, technol-
ogy appraisal.
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be relevant. Current population adjustment methods can only
produce estimates valid for the population represented by the
aggregate study unless further assumptions are made, which
may not represent the decision at hand; this has been largely over-
looked in appraisals to date (although note that several of the TAs
we identified pre-date published guidance).
For anchored comparisons there should be clear prior justifica-
tion for effect modification, based on empirical evidence from
previous studies and/or clinical expertise. Appraisals reporting
anchored comparisons to date did not provide any such justifica-
tion. Unanchored comparisons require reliable predictions of
absolute effects by means of adjustment for both prognostic
and effect-modifying covariates, and are highly susceptible to
unobserved confounding due to a lack of randomisation. Simply
adjusting for all available covariates, as is currently common prac-
tice, is not sufficient.
For unanchored comparisons to be impactful, covariates
should be selected with predictive performance in mind and esti-
mates of the potential range of residual bias are required; other-
wise, the amount of bias in the estimates is unknown and may
even be larger than for an unadjusted comparison. This is not
easy to achieve (some suggestions are made in (6)), but without
such reassurance appraisal committees are likely to remain justi-
fiably wary of unanchored analyses. Many of the above issues can
be mitigated, at least in part, by the availability of IPD from all
studies in an analysis, and thus the increased sharing of IPD is
greatly encouraged.
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